A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity

Sponsor
Novo Nordisk A/S
Study ID
NCT07557953
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 64 Years
Healthy Volunteers
Not accepted

Interventions

  • Cagrilintide — DRUG
    Cagrilintide is administered subcutaneously .
  • Placebo Cagrilintide — DRUG
    Placebo Cagrilintide is administered subcutaneously.

Study Details

The study is testing cagrilintide, a study medicine, to understand how it affects food intake and appetite in people with overweight or obesity. Participants will receive either cagrilintide or placebo, and which treatment participants get is decided by chance. Cagrilintide is the treatment being tested, while placebo looks like the study medicine but does not contain any active medicine. The study will last for about 30 weeks.

Key Dates

Start date
Apr 30, 2026
Status verified
May 2026
Primary completion
Apr 13, 2027
Completion
Apr 13, 2027

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cagrilintide
    Participant will receive Cagrilintide subcutaneously once weekly for up to 17 weeks.
  • Placebo Comparator: Placebo Cagrilintide
    Participant will receive placebo matched to Cagrilintide subcutaneously once weekly for up to 17 weeks.

Primary Outcome Measure

Relative change in total energy intake across ad libitum breakfast, lunch, evening meal and snack box [ Time Frame: From baseline (Day 2) to end of treatment (Day 127) ]

Central Contacts

Related Studies